A phase II trial of cisplatin and vinorelbine in patients with recurrent or metastatic squamous cell carcinoma of the head and neck

Abstract

The combination of cisplatin and vinorelbine is moderately active in patients with recurrent or metastatic carcinomas of the head and neck and avoids the inconvenience of prolonged infusions of 5-fluorouracil.

A phase II study using vinorelbine and continuous 5-fluorouracil in patients with advanced head and neck cancer

“…In this study we found a median survival of 6.6 months which is comparable to the results of other studies using combination chemotherapy [11,14]. The median time to progression of 4.7 months is also comparable to other studies [14].…”

“…Although our response rates were similar to those in other studies [10,11,13,14] we had expected that the toxicity profile to be more favourable, but especially leukopenia and infections were more pronounced than expected. Leukopenia was the most common reason for reducing dose of vinorelbine.…”

Standard, and novel cytotoxic and molecular-targeted, therapies for HNSCC: an evidence-based review

“…For other novel cytotoxic agents, two phase II studies were identified of gemcitabine, alone [29] or in combination with paclitaxel [30]; three phase II trials of vinorelbine, with cisplatin [31] plus 5-fluorouracil [32], or with bleomycin plus methotrexate [33], were found.…”

Concurrent use of vinorelbine and gefitinib induces supra-additive effect in head and neck squamous cell carcinoma cell lines

“…In phase II studies vinorelbine has proved to be a potential and active drug against advanced HNSCC (Degardin et al 1998;Testolin et al 1994). Vinorelbine combined with cisplatin alone or with cisplatin and 5-FU followed by hyperfractionated irradiation has shown encouraging results in the treatment of advanced HNSCC (Espinosa et al 2002;Orecchia et al 2002). Vinorelbine has a relatively mild toxicity proWle and can be used even for elderly and poor performance status patients (Gridelli et al 1997).…”